Icecure Medical (ICCM) has released an update.
IceCure Medical Ltd. has announced that the FDA will review its ProSense® System, a minimally invasive cryoablation technology for tumor treatment, in an Advisory Panel meeting set for the fourth quarter of 2024, with a decision expected by early 2025. The company’s CEO expressed confidence in the potential approval, citing positive ICE3 study results and high patient satisfaction rates. ProSense® is already approved in several countries and is positioned as an alternative to surgical tumor removal, promising to enhance patient recovery and reduce surgical risks.
For further insights into ICCM stock, check out TipRanks’ Stock Analysis page.
